Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • In Brief
  • Published:

Infection

Predicting treatment failure in urinary tract infections

Nature Reviews Urology volume 12, page 63 (2015)Cite this article

Subjects

The Escherichia coli O25b/sequence type 131 (ST131) clone can be used to predict treatment failure in patients with urinary tract infections, say researchers. Can et al. studied 294 patients who had acute urinary cystitis with isolation of E. coli in their urine cultures. They followed patients for clinical cure after 10 days of treatment and found that detection of the E. coli O25:ST131 clone by PCR was a significant risk factor for treatment failure.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Can, F. et al. Emerging Escherichia coli O25b/ST131 clone preducts treatment failure in urinary tract infections. Clin. Infect. Dis. 10.1093/cid/ciu864

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Predicting treatment failure in urinary tract infections. Nat Rev Urol 12, 63 (2015). https://doi.org/10.1038/nrurol.2014.348

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrurol.2014.348

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing